newsfilter
← Latest News
GlobeNewswire·

YD Bio Limited Reports Full Year 2025 Financial Results

  • YD Bio Limited reported full-year 2025 net revenue of $597,000, representing a 17% increase from 2024, driven primarily by higher pharmaceutical sales volumes & new product launches.
  • Net loss for 2025 widened to $8.3 million from $1.4 million in 2024, largely due to a $3.2 million increase in the fair value change of warrant liabilities & higher operating expenses.
  • Operating expenses rose to $5.4 million in 2025 from $1.6 million in 2024, attributed to increased professional fees, R&D costs for licensed patents, & expanded staff costs.
  • Cash & cash equivalents reached $6.0 million as of December 31, 2025, bolstered by a $13.9 million equity raise following the company's business combination with Breeze Holdings Acquisition Corp.
  • The company shifted its sales mix toward lower-margin pharmaceuticals like Keytruda, which generated $133,138 in revenue, while medical product sales declined due to discontinued items & customer strategy changes.
  • R&D expenditures increased by $1.1 million to $1.6 million to secure essential patents & technological know-how for clinical service infrastructure.
  • Strategic milestones for 2026 include submitting Investigational New Drug applications to the FDA for Dry Eye Disease & Age-Related Macular Degeneration & advancing the OkaiDx™ Pancreatic Cancer Early Detection Program.
  • YD Bio announced strategic expansions including a non-binding merger agreement with EG BioMed, a binding Letter of Intent to acquire Safe Save Medical, & a strategic alliance with YC Biotech.
  • The EG Telehealth Platform launched in March 2026, currently offering CLIA- & CAP-certified laboratory services across 44 U.S. states, Washington D.C., & Guam.